Doramapimod
Based on 51 publication(s) in Google Scholar
Doramapimod (BIRB 796) is an orally active, highly potent p38 MAPK inhibitor, which has an IC50 for p38α=38 nM, for p38β=65 nM, for p38γ=200 nM, and for p38δ=520 nM. Doramapimod has picomolar affinity for p38 kinase (Kd=0.1 nM). Doramapimod also inhibits B-Raf with an IC50 of 83 nM.
For research use only. We do not sell to patients.
- Purity: 99.93%
- CAS No.: 285983-48-4
- Formula: C31H37N5O3
- Molecular Weight:527.66
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 1 year , -20°C, 6 months
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Protocol
- Purity & Documentation
- References
-
Help & FAQs
-
Anti-Infection Compound Library
HY-L002
-
Immunology/Inflammation Compound Library
HY-L007
-
Kinase Inhibitor Library
HY-L009
-
MAPK Compound Library
HY-L010
-
Anti-Cancer Compound Library
HY-L025
-
Clinical Compound Library
HY-L026
-
Autophagy Compound Library
HY-L029
-
Drug Repurposing Compound Library
HY-L035
-
Reprogramming Compound Library
HY-L039
-
Oxygen Sensing Compound Library
HY-L045
-
Ferroptosis Compound Library
HY-L051
-
Anti-COVID-19 Compound Library
HY-L052
-
Pyroptosis Compound Library
HY-L059
-
Orally Active Compound Library
HY-L061
-
Glutamine Metabolism Compound Library
HY-L064
-
Anti-Lung Cancer Compound Library
HY-L075
-
Anti-Pancreatic Cancer Compound Library
HY-L077
-
Anti-Cancer Metabolism Compound Library
HY-L083
-
Neurodegenerative Disease-related Compound Library
HY-L086
-
Anti-Obesity Compound Library
HY-L087
-
Angiogenesis-Related Compound Library
HY-L088
-
Anti-Liver Cancer Compound Library
HY-L101
-
Anti-Colorectal Cancer Compound Library
HY-L103
-
Antidepressant Compound Library
HY-L108
-
Human Metabolite Library
HY-L123
-
Anti-Prostate Cancer Compound Library
HY-L124
-
Anti-Pulmonary Fibrosis Compound Library
HY-L125
-
Heterocyclic Compound Library
HY-L138
-
Pain-Related Compound Library
HY-L139
-
Membrane Receptor-targeted Compound Library
HY-L150
-
Mitochondrial Toxicity Compound Library
HY-L155
-
Highly Selective Inhibitors Library
HY-L158
-
Cell Death Library
HY-L162
-
Serine/Threonine Kinase Inhibitor Library
HY-L164
-
Anti-Ovarian Cancer Compound Library
HY-L173
-
Multi-Target Compound Library
HY-L176
-
Bioactive Compound Library Max
HY-L181
-
Anti-Aging Compound Library Mini
HY-L034M
-
Kinase Inhibitor Library Mini
HY-L009M
-
MCE Bioactive Compound Library
HY-L001V
-
Drug Repurposing Compound Library Plus
HY-L035P
-
Clinical Compound Library Plus
HY-L026P
-
Bioactive Compound Library
HY-L001
-
Anti-Gastric Cancer Compound Library
HY-L184
-
Anti-Brain Cancer Compound Library
HY-L188
-
Protein Kinase Compound Library
HY-L196
-
Cell Proliferation Compound Library
HY-L201
-
High-Throughput Bioactive Compound Library
HY-L205
-
Anti-Rheumatic Arthritis Compound Library
HY-L210
-
Mass Spectrometry Human Metabolite Library
HY-L215
-
Posttranslational Modification Library
HY-L226
-
RNA Binding Bioactive Compound Library
HY-L248
-
Lactylation Compound Library
HY-L249
Publications Citing Use of MedChemExpress (MCE) Doramapimod
More- Nature. 2019 Jul;571(7763):127-131. [Abstract]
- Nat Immunol. 2025 Oct;26(10):1660-1672. [Abstract]
- Cell Res. 2020 Jul;30(7):574-589. [Abstract]
- Sci Transl Med. 2018 Jul 18;10(450):eaaq1093. [Abstract]
- Exp Mol Med. 2021 Sep;53(9):1366-1378. [Abstract]
- Redox Biol. 2024 Sep 6:76:103344. [Abstract]
- Engineering. 2025 Mar 4.
- EBioMedicine. 2015 Nov 19;2(12):1944-56. [Abstract]
- Cell Rep Med. 2025 Sep 19:102357. [Abstract]
- Cell Death Dis. 2022 Oct 8;13(10):860. [Abstract]
- Cell Death Dis. 2016 Feb 25;7(2):e2119. [Abstract]
- Br J Anaesth. 2025 Mar;134(3):759-771. [Abstract]
- Proc Natl Acad Sci U S A. 2023 Jan 31;120(5):e2213777120. [Abstract]
- Dev Cell. 2021 Dec 20;56(24):3334-3348.e6. [Abstract]
- Phytomedicine. 2026 Feb:151:157795. [Abstract]
- EMBO Mol Med. 2025 Mar;17(3):535-562. [Abstract]
- Biomed Pharmacother. 2024 Jan:170:115987. [Abstract]
- Anal Chem. 2021 Nov 16;93(45):14985-14995. [Abstract]
- Immun Ageing. 2025 Jul 15;22(1):30. [Abstract]
- Cell Prolif. 2024 Jul;57(7):e13618. [Abstract]
- Chem Biol Interact. 2025 Oct 22:420:111693. [Abstract]
- Cells. 2023 Feb 20;12(4):664. [Abstract]
- Life Sci. 2025 May 11:123698. [Abstract]
- PLoS Pathog. 2025 Jul 3;21(7):e1013258. [Abstract]
- Eur J Pharmacol. 2025 Oct 10:1007:178239. [Abstract]
- Cancer Biol Ther. 2022 Dec 31;23(1):69-82. [Abstract]
- iScience. 2025 Dec 9.
- iScience. 2025 Dec 26.
- Toxics. 2024 Aug 19;12(8):607. [Abstract]
- Transl Oncol. 2022 May:19:101391. [Abstract]
- Sci Rep. 2025 Jul 2;15(1):23648. [Abstract]
- Cell Signal. 2023 May:105:110607. [Abstract]
- Biol Reprod. 2026 Feb 20:ioag038. [Abstract]
- Discov Oncol. 2024 Nov 19;15(1):678. [Abstract]
- Onco Targets Ther. 2018 Nov 2;11:7777-7786. [Abstract]
- Tissue Cell. 2025 Dec 5:99:103263. [Abstract]
- Tissue Cell. 2025 Sep 17:98:103145. [Abstract]
- Tissue Cell. 2024 Nov 28:92:102643. [Abstract]
- Theriogenology. 2024 Dec 2:234:9-18. [Abstract]
- Chin J Integr Med. 2025 Jul;31(7):613-623. [Abstract]
- In Vitro Cell Dev Biol Anim. 2025 Oct 17. [Abstract]
- bioRxiv. 2026 Jan 25.
- bioRxiv. 2025 Jun 3:2025.06.02.657064. [Abstract]
- bioRxiv. 2025 Feb 23:2025.02.19.639175. [Abstract]
- bioRxiv. 2025 January 31.
- Patent. US20240263208A1.
- bioRxiv. 2024 Mar 13.
- Oxid Med Cell Longev. 2023 Feb 10:2023:6726654. [Abstract]
- Curr Protoc Cell Biol. 2018 Dec;81(1):e62. [Abstract]
- Dis Markers. 2018 Apr 17:2018:7413027. [Abstract]
- Technische Universitat Dresden. 2017.
Customer Validation & Images
-
WB
-
WB
-
IF
-
2D/3D Cell Culture and Differentiation
-
IP
Biological Activity
|
p38α 38 nM (IC50) |
p38β 65 nM (IC50) |
p38δ 520 nM (IC50) |
p38γ 200 nM (IC50) |
B-Raf 83.4 nM (IC50) |
Abl 14600 nM (IC50) |
p38 MAP kinase 0.1 nM (Kd) |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| PBMC | IC50 |
15 nM
Compound: BIRB-796
|
Antiinflammatory activity in LPS-stimulated human isolated PBMC assessed as inhibition of TNFalpha production preincubated for 1 hr prior to LPS-challenge by ELISA
Antiinflammatory activity in LPS-stimulated human isolated PBMC assessed as inhibition of TNFalpha production preincubated for 1 hr prior to LPS-challenge by ELISA
|
[PMID: 21888439] |
| PBMC | IC50 |
30 nM
Compound: BIRB-796
|
Inhibition of LPS-stimulated TNFalpha release in human PBMC by ELISA
Inhibition of LPS-stimulated TNFalpha release in human PBMC by ELISA
|
[PMID: 18602262] |
| THP-1 | EC50 |
18 nM
Compound: 45
|
Inhibition of LPS-induced tumor necrosis factor-alpha (TNF-alpha) production in THP-1 cells
Inhibition of LPS-induced tumor necrosis factor-alpha (TNF-alpha) production in THP-1 cells
|
[PMID: 12086485] |
| THP-1 | IC50 |
0.013 μM
Compound: BIRB-796
|
Inhibition of LPS-induced TNFalpha production in human THP1 cells
Inhibition of LPS-induced TNFalpha production in human THP1 cells
|
[PMID: 18325768] |
| THP-1 | IC50 |
18 nM
Compound: 1, BIRB-796
|
Inhibition of LPS-induced TNFalpha production in human THP1 cells
Inhibition of LPS-induced TNFalpha production in human THP1 cells
|
[PMID: 19356929] |
| THP-1 | IC50 |
18 nM
Compound: BIRB-796
|
Inhibition of LPS-induced TNFalpha production in THP1 cells
Inhibition of LPS-induced TNFalpha production in THP1 cells
|
[PMID: 17560108] |
| THP-1 | IC50 |
18 nM
Compound: BIRB-796
|
Inhibition of LPS-stimulated TNFalpha production in human THP1 cells
Inhibition of LPS-stimulated TNFalpha production in human THP1 cells
|
[PMID: 18462940] |
| U-937 | IC50 |
15 nM
Compound: 4; BIRB-796
|
Antiinflammatory activity in differentiated human U937 cells assessed as inhibition of LPS-induced TNFalpha production preincubated for 2 hrs followed by LPS-stimulation for 4 hrs by sandwich ELISA relative to vehicle-treated control
Antiinflammatory activity in differentiated human U937 cells assessed as inhibition of LPS-induced TNFalpha production preincubated for 2 hrs followed by LPS-stimulation for 4 hrs by sandwich ELISA relative to vehicle-treated control
|
[PMID: 26800309] |
Doramapimod (BIRB 796) is usually associated with inflammation because of its role in T-cell proliferation and cytokine production[1].
Doramapimod (BIRB 796) blocks the stress-induced phosphorylation of the scaffold protein SAP97, further establishing that this is a physiological substrate of SAPK3/p38γ. The binding of Doramapimod to the p38 MAPKs or JNK1/2 is impairing their phosphorylation by the upstream kinase MKK6 or MKK4[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
The Doramapimod (BIRB 796) treatment slightly reduces blood pressure (166±7 mm Hg at week 7; P<0.05), whereas SD rats are normotensive (123±3 mm Hg). Despite the reduction in blood pressure, untreated and Doramapimod-treated dTGRs have similar heart weight and cardiac hypertrophy indices (heart-to-tibia ratio), which are significantly higher compare with nontransgenic SD rats (310±6 versus 307±6 versus 206±5 mg/cm, respectively; P<0.05)[5].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 285983-48-4
-
Appearance Solid
-
Molecular Weight 527.66
-
Formula C31H37N5O3
-
Color Off-white to gray
-
SMILES
O=C(NC1=CC(C(C)(C)C)=NN1C2=CC=C(C)C=C2)NC3=C4C=CC=CC4=C(OCCN5CCOCC5)C=C3
-
Synonyms
BIRB 796
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 1 year -20°C 6 months
Publications (51)
-
Journal Impact Factor
-
Most Recent
-
Nature
2019 Jul;571(7763):127-131. PMID: 31243371
Doramapimod purchased from MedChemExpress. Usage Cited in: Nature. 2019 Jul;571(7763):127-131. [Abstract]
BIRB 796 (1 μM, 4.5 h) did not abrogate EGF-induced pUGDH in A549 cells stably expressing Flag–UGDH.
-
Nat Immunol
Delaying pyroptosis with an AI-screened gasdermin D pore blocker mitigates inflammatory response. [Abstract]2025 Oct;26(10):1660-1672. PMID: 40954252 -
Cell Res
Elimination of senescent cells by β-galactosidase-targeted prodrug attenuates inflammation and restores physical function in aged mice. [Abstract]2020 Jul;30(7):574-589. PMID: 32341413
Doramapimod purchased from MedChemExpress. Usage Cited in: Cell Res. 2020 Jul;30(7):574-589. [Abstract]
Birb 796 (0.1, 0.3, 1, and 3 μM, 3 days) impaired the ability of SSK1 (0.5 μM,3 days) to specifically kill senescent HUVEC.
-
Sci Transl Med
PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells. [Abstract]2018 Jul 18;10(450):eaaq1093. PMID: 30021885 -
Exp Mol Med
MRTF-A-NF-κB/p65 axis-mediated PDL1 transcription and expression contributes to immune evasion of non-small-cell lung cancer via TGF-β. [Abstract]2021 Sep;53(9):1366-1378. PMID: 34548615 -
Redox Biol
2024 Sep 6:76:103344. PMID: 39265499
Doramapimod purchased from MedChemExpress. Usage Cited in: Redox Biol. 2024 Sep 6:76:103344. [Abstract]
BIRB 796 (DORA, 10 μM, 4 h) inhibited the expression of p-p38 MAPK induced by LPS (1000 ng/mL) in 10T1/2 cells.
Doramapimod purchased from MedChemExpress. Usage Cited in: Redox Biol. 2024 Sep 6:76:103344. [Abstract]
BIRB 796 (DORA, 10 μM, 4 h) inhibited the mitochondrial recruitment of DRP1 and the fission induced by LPS (1000 ng/mL) in 10T1/2 cells.
-
Doramapimod purchased from MedChemExpress. Usage Cited in: Engineering. 2025 Mar 4.
BIRB 796 (10 μM, 36 h) inhibited the expression of p-p38 MAPK induced by LPS (200 ng/mL) in THP-1 cells.
-
EBioMedicine
PP2AC Level Determines Differential Programming of p38-TSC-mTOR Signaling and Therapeutic Response to p38-Targeted Therapy in Colorectal Cancer. [Abstract]2015 Nov 19;2(12):1944-56. PMID: 26844273 -
Cell Rep Med
Drug screening in 3D microtumors reveals DDR1/2-MAPK12-GLI1 as a vulnerability in cancer-associated fibroblasts. [Abstract]2025 Sep 19:102357. PMID: 40975064 -
Cell Death Dis
Inhibition of p38 MAPK or immunoproteasome overcomes resistance of chronic lymphocytic leukemia cells to Bcl-2 antagonist venetoclax. [Abstract]2022 Oct 8;13(10):860. PMID: 36209148 -
Cell Death Dis
2016 Feb 25;7(2):e2119. PMID: 26913608 -
Br J Anaesth
Kappa opioid receptor internalisation-induced p38 nuclear translocation suppresses glioma progression. [Abstract]2025 Mar;134(3):759-771. PMID: 39741108 -
Proc Natl Acad Sci U S A
Activation of the NLRP1 inflammasome in human keratinocytes by the dsDNA mimetic poly(dA:dT). [Abstract]2023 Jan 31;120(5):e2213777120. PMID: 36693106 -
Dev Cell
Endoderm development requires centrioles to restrain p53-mediated apoptosis in the absence of ERK activity. [Abstract]2021 Dec 20;56(24):3334-3348.e6. PMID: 34932949 -
Phytomedicine
Complementary roles and synergy of the Ephedra-Glycyrrhiza herb pair across murine models of respiratory symptoms and poly(I:C)-induced pneumonia. [Abstract]2026 Feb:151:157795. PMID: 41539102 -
EMBO Mol Med
Portimine A toxin causes skin inflammation through ZAKα-dependent NLRP1 inflammasome activation. [Abstract]2025 Mar;17(3):535-562. PMID: 39948420 -
Biomed Pharmacother
Inhibiting the MAPK pathway improves heart failure with preserved ejection fraction induced by salt-sensitive hypertension. [Abstract]2024 Jan:170:115987. PMID: 38056241 -
Anal Chem
Identifying Protein-Drug Interactions in Cell Lysates Using Histidine Hydrogen Deuterium Exchange. [Abstract]2021 Nov 16;93(45):14985-14995. PMID: 34735131 -
Immun Ageing
p38 mitogen-activated protein kinase drives senescence in CD4+ T lymphocytes and increases their pathological potential. [Abstract]2025 Jul 15;22(1):30. PMID: 40665343 -
Cell Prolif
Rack1-mediated ferroptosis affects hindgut development in rats with anorectal malformations: Spatial transcriptome insights. [Abstract]2024 Jul;57(7):e13618. PMID: 38523594 -
Chem Biol Interact
A novel non-nad-based PARP1 inhibitor, Japoflavone B, triggered Caspase-3/GSDME-mediated pyroptosis through ROS/p38/p53 pathway in NSCLC. [Abstract]2025 Oct 22:420:111693. PMID: 40754060 -
Cells
SB202190 Predicts BRAF-Activating Mutations in Primary Colorectal Cancer Organoids via Erk1-2 Modulation. [Abstract]2023 Feb 20;12(4):664. PMID: 36831331 -
Life Sci
OASL activates MAPK to drive psoriatic pathogenesis: Astilbin targeting this axis improves metabolic-inflammation crosstalk. [Abstract]2025 May 11:123698. PMID: 40360089 -
PLoS Pathog
The non-structural protein of SFTSV activates NLRP1 and CARD8 inflammasome through disrupting the DPP9-mediated ternary complex. [Abstract]2025 Jul 3;21(7):e1013258. PMID: 40608794 -
Eur J Pharmacol
Adenine suppresses inflammatory response in vascular smooth muscle cells via modulating AMPK/p53/NF-κB cascade. [Abstract]2025 Oct 10:1007:178239. PMID: 41075915 -
Cancer Biol Ther
Repeated treatments of Capan-1 cells with PARP1 and Chk1 inhibitors promote drug resistance, migration and invasion. [Abstract]2022 Dec 31;23(1):69-82. PMID: 35000525 -
-
-
Toxics
Evaluation of THP-1 and Jurkat Cell Lines Coculture for the In Vitro Assessment of the Effects of Immunosuppressive Substances. [Abstract]2024 Aug 19;12(8):607. PMID: 39195709 -
Transl Oncol
TMBIM1 promotes proliferation and attenuates apoptosis in glioblastoma cells by targeting the p38 MAPK signalling pathway. [Abstract]2022 May:19:101391. PMID: 35279540 -
Sci Rep
2025 Jul 2;15(1):23648. PMID: 40603446 -
Cell Signal
2023 May:105:110607. PMID: 36690134 -
Biol Reprod
KAT2A contributes to premature ovarian insufficiency by activating the P38/MAPK signaling pathway to drive granulosa cell dysfunction†. [Abstract]2026 Feb 20:ioag038. PMID: 41717786 -
Discov Oncol
Aberrant expression of MRAS and HEG1 as the biomarkers for osimertinib resistance in LUAD. [Abstract]2024 Nov 19;15(1):678. PMID: 39560891 -
Onco Targets Ther
Resveratrol, an activator of SIRT1, induces protective autophagy in non-small-cell lung cancer via inhibiting Akt/mTOR and activating p38-MAPK. [Abstract]2018 Nov 2;11:7777-7786. PMID: 30464525 -
Tissue Cell
2025 Dec 5:99:103263. PMID: 41365188 -
Tissue Cell
Asiatic acid reverses cisplatin resistance in A549/DDP cells by activating the P38 MAPK/Slug pathway. [Abstract]2025 Sep 17:98:103145. PMID: 41014726 -
Tissue Cell
The Shh-p38-NFATc1 signaling pathway is essential for osteoclastogenesis during tooth eruption. [Abstract]2024 Nov 28:92:102643. PMID: 39612595 -
Theriogenology
RNA-seq analysis of the biological process and regulatory signal of TGF-β1-mediated changes in ovarian granulosa cells in small-tail Han sheep. [Abstract]2024 Dec 2:234:9-18. PMID: 39631254 -
Chin J Integr Med
Liang-Ge-San Decoction Ameliorates Acute Respiratory Distress Syndrome via Suppressing p38MAPK-NF-κ B Signaling Pathway. [Abstract]2025 Jul;31(7):613-623. PMID: 39636495 -
In Vitro Cell Dev Biol Anim
Cadmium-induced nucleus pulposus derived mesenchymal stem cells apoptosis via MAPK signaling pathway contributes to IVD degeneration. [Abstract]2025 Oct 17. PMID: 41107668 -
-
bioRxiv
2025 Jun 3:2025.06.02.657064. PMID: 40502089 -
bioRxiv
2025 Feb 23:2025.02.19.639175. PMID: 40027792 -
-
-
-
Oxid Med Cell Longev
JFD, a Novel Natural Inhibitor of Keap1 Alkylation, Suppresses Intracellular Mycobacterium Tuberculosis Growth through Keap1/Nrf2/SOD2-Mediated ROS Accumulation. [Abstract]2023 Feb 10:2023:6726654. PMID: 36819778 -
Curr Protoc Cell Biol
2018 Dec;81(1):e62. PMID: 30239150 -
Dis Markers
Knockdown of Heparanase Suppresses Invasion of Human Trophoblasts by Activating p38 MAPK Signaling Pathway. [Abstract]2018 Apr 17:2018:7413027. PMID: 29849826 -
Solvent & Solubility
DMSO : 100 mg/mL (189.52 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Ethanol : 33.33 mg/mL (63.17 mM; Need ultrasonic)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (3.94 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 2.08 mg/mL (3.94 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 2.08 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocol
Human embryonic kidney (HEK) 293 and HeLa cells are exposed to 0.5 M sorbitol for 30 min or 100 ng/mL EGF for 10 min and then lysed in buffer A (50 mM Tris-HCl, pH 7.5, 1 mM EGTA, 1 mM EDTA, 1 mM sodium orthovanadate, 10 mM sodium fluoride, 50 mM sodium β-glycerophosphate, 5 mM pyrophosphate, 0.27 M sucrose, 0.1 mM phenylmethylsulfonyl fluoride, 1% (v/v) Triton X-100) plus 0.1% (v/v) 2-mercaptoethanol and Complete proteinase inhibitor mixture. Lysates are centrifuged at 18,000× g for 5 min at 4°C, and the supernatants are removed, quick-frozen in liquid nitrogen, and stored at -20°C until use. When required, cells are preincubated for 1 h without or with 10 μM SB 203580 or 10 μM PD 184352 or with different concentrations of Doramapimod for the times indicated in the figures[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Mice[4]
Athymic nude mice (BALB/c-nu/nu), 6 to 8 weeks of age and weighing 18 to 24 g, are used. The mice are treated with Doramapimod (10 mg/kg p.o., every 3 days×5). The body weights of the animals and the two perpendicular tumor diameters (A and B) are recorded every 3 days, and the tumor volume (V) is estimated.
Rats[5]
Male transgenic dTGRs (RCC Ltd) and age-matched nontransgenic Sprague-Dawley (SD) rats (MDC) are use. 2 different protocols are performed. In protocol 2, untreated dTGR (n=15), dTGR+BIRB796 (30 mg/kg per day in the diet for 3 weeks; n=11), and SD (n=8 each group) rats are analyzed. Systolic blood pressure is measured weekly by tail cuff. Twenty-four-hour urine samples are collected in metabolic cages from weeks 5 to 7. Serum is collected at week 7. Serum creatinine and cystatin C are measured by clinical routine assays. Urinary rat albumin is determined by enzyme-linked immunosorbent assay. The aim of protocol 2 is to focus on electrophysiological alterations and mortality. Untreated dTGR (n=10), dTGR+BIRB796 (n=10), and SD (n=10) rats are studied up to week 8.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Purity & Documentation
-
Data Sheet (285 KB)
-
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Portuguese - PT (396 KB)
-
Handling Instructions (2659 KB)
References
[1]. Dietrich J, et al. The design, synthesis, and evaluation of 8 hybrid DFG-out allosteric kinase inhibitors. Bioorg Med Chem. 2010 Aug 1;18(15):5738-48 [Content Brief]
[2]. Cicenas J, et al. JNK, p38, ERK, and SGK1 Inhibitors in Cancer. Cancers (Basel). 2017 Dec 21;10(1). pii: E1. [Content Brief]
[3]. Kuma Y, et al. BIRB796 inhibits all p38 MAPK isoforms in vitro and in vivo. J Biol Chem, 2005, 280(20), 19472-19479. [Content Brief]
[4]. He D, et al. BIRB796, the inhibitor of p38 mitogen-activated protein kinase, enhances the efficacy of chemotherapeutic agents in ABCB1 overexpression cells. PLoS One. 2013;8(1):e54181. [Content Brief]
[5]. Park JK, et al. p38 mitogen-activated protein kinase inhibition ameliorates angiotensin II-induced target organ damage. Hypertension. 2007 Mar;49(3):481-9. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| Ethanol / DMSO | 1 mM | 1.8952 mL | 9.4758 mL | 18.9516 mL | 47.3790 mL |
| 5 mM | 0.3790 mL | 1.8952 mL | 3.7903 mL | 9.4758 mL | |
| 10 mM | 0.1895 mL | 0.9476 mL | 1.8952 mL | 4.7379 mL | |
| 15 mM | 0.1263 mL | 0.6317 mL | 1.2634 mL | 3.1586 mL | |
| 20 mM | 0.0948 mL | 0.4738 mL | 0.9476 mL | 2.3689 mL | |
| 25 mM | 0.0758 mL | 0.3790 mL | 0.7581 mL | 1.8952 mL | |
| 30 mM | 0.0632 mL | 0.3159 mL | 0.6317 mL | 1.5793 mL | |
| 40 mM | 0.0474 mL | 0.2369 mL | 0.4738 mL | 1.1845 mL | |
| 50 mM | 0.0379 mL | 0.1895 mL | 0.3790 mL | 0.9476 mL | |
| 60 mM | 0.0316 mL | 0.1579 mL | 0.3159 mL | 0.7896 mL | |
| DMSO | 80 mM | 0.0237 mL | 0.1184 mL | 0.2369 mL | 0.5922 mL |
| 100 mM | 0.0190 mL | 0.0948 mL | 0.1895 mL | 0.4738 mL |
Powered by Bioz